S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics, a subsidiary of Biocon Limited, to ‘BB+’ from ‘BB’. The rating agency has also maintained a stable outlook for the company. This upgrade is a testament to Biocon Biologics’ strong business profile, driven by its robust product portfolio, expanding global presence, and significant investments in research and development.<\/p>\n
The ‘BB+’ rating reflects Biocon Biologics’ established position in the biosimilars market, with a diverse portfolio of products across diabetes, oncology, and immunology. The company’s commitment to innovation and quality has enabled it to build a strong reputation in the industry. S&P Global Ratings noted that Biocon Biologics’ revenue growth is expected to remain robust, driven by the increasing demand for biosimilars globally.<\/p>\n
The rating agency also highlighted the company’s improving profitability, driven by better operating efficiencies and a favorable product mix. Biocon Biologics’ EBITDA margin is expected to remain stable, supported by its ability to manage costs and maintain pricing power. The company’s debt-to-EBITDA ratio is expected to remain moderate, providing it with the flexibility to pursue growth opportunities.<\/p>\n
The stable outlook reflects S&P Global Ratings’ expectation that Biocon Biologics will maintain its strong business profile, driven by its established product portfolio and expanding global presence. The company’s significant investments in research and development are expected to yield new product launches, further enhancing its competitive position.<\/p>\n
The upgrade is a significant milestone for Biocon Biologics, as it reflects the company’s ability to execute its strategy and deliver strong financial performance. The ‘BB+’ rating will provide the company with better access to capital markets, enabling it to pursue its growth plans and expand its global footprint. Biocon Biologics’ strong ratings will also enhance its credibility with customers, partners, and investors, further solidifying its position as a leading player in the biosimilars market.<\/p>\n
Overall, the rating upgrade by S&P Global Ratings is a testament to Biocon Biologics’ strong fundamentals and growth prospects. The company’s commitment to innovation, quality, and customer satisfaction has enabled it to establish a strong position in the industry, and the ‘BB+’ rating reflects its ability to maintain this position and pursue new opportunities for growth.<\/p>\n","protected":false},"excerpt":{"rendered":"
S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics, a subsidiary of Biocon Limited, to ‘BB+’ from ‘BB’. The rating agency has also maintained a stable outlook for the company. This upgrade is a testament to Biocon Biologics’ strong business profile, driven by its robust product portfolio, expanding global presence, and […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[14,2],"tags":[],"class_list":["post-89877","post","type-post","status-publish","format-standard","hentry","category-biocon","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89824,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/19\/biocon-expects-robust-q3-performance-fueled-by-biosimilar-growth\/","url_meta":{"origin":89877,"position":0},"title":"Biocon Expects Robust Q3 Performance Fueled by Biosimilar Growth","author":"Team Small News","date":"January 19, 2026","format":false,"excerpt":"Biocon, a leading biopharmaceutical company, is expected to have a strong third quarter in the fiscal year 2026 (Q3FY26). The company's biosimilars segment is anticipated to drive this growth, with key products such as bStelara playing a significant role. Analysts predict substantial revenue growth, driven by the increasing adoption of\u2026","rel":"","context":"In "Biocon"","block_context":{"text":"Biocon","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/biocon\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89898,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/02\/03\/glenmark-pharmaceuticals-sets-sights-on-fy28-for-debut-of-oncology-drugs-and-expansion-of-profit-margins-reports-etpharma\/","url_meta":{"origin":89877,"position":1},"title":"Glenmark Pharmaceuticals sets sights on FY28 for debut of oncology drugs and expansion of profit margins, reports ETPharma.","author":"Team Small News","date":"February 3, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89870,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/27\/lupin-achieves-top-esg-rating-from-cdp-for-its-efforts-in-addressing-climate-change-and-water-security\/","url_meta":{"origin":89877,"position":2},"title":"Lupin achieves top ESG rating from CDP for its efforts in addressing climate change and water security.","author":"Team Small News","date":"January 27, 2026","format":false,"excerpt":"Lupin, a global pharmaceutical leader, has been recognized for its exceptional sustainability efforts, receiving the highest \"A\" leadership rating from the Climate Disclosure Project (CDP) for both Climate Change and Water Security. This prestigious recognition solidifies Lupin's position among the world's most sustainable and transparent companies. The double \"A\" rating\u2026","rel":"","context":"In "Lupin"","block_context":{"text":"Lupin","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/lupin\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89848,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/24\/lupin-earns-top-cdp-a-rating-for-efforts-in-combating-climate-change-and-conserving-water\/","url_meta":{"origin":89877,"position":3},"title":"Lupin Earns Top CDP A Rating for Efforts in Combating Climate Change and Conserving Water","author":"Team Small News","date":"January 24, 2026","format":false,"excerpt":"Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest 'A' leadership rating from the Climate Disclosure Project (CDP) for its exceptional performance in Climate Change and Water Security. This recognition is a testament to Lupin's commitment to sustainability and transparency,\u2026","rel":"","context":"In "Lupin"","block_context":{"text":"Lupin","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/lupin\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89844,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/23\/lupin-achieves-top-esg-score-from-cdp-for-efforts-in-combating-climate-change-and-ensuring-water-security-reported-by-chennai-patrika\/","url_meta":{"origin":89877,"position":4},"title":"Lupin Achieves Top ESG Score from CDP for Efforts in Combating Climate Change and Ensuring Water Security – Reported by Chennai Patrika.","author":"Team Small News","date":"January 23, 2026","format":false,"excerpt":"Lupin Limited, a global pharmaceutical major, has achieved a significant milestone in its sustainability efforts by receiving the highest 'A' leadership rating from the Climate Disclosure Project (CDP) for its exceptional accomplishments in Climate Change and Water Security. This recognition solidifies Lupin's position as a global leader in championing sustainability\u2026","rel":"","context":"In "Lupin"","block_context":{"text":"Lupin","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/lupin\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89855,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/25\/lupin-achieves-prestigious-cdp-double-a-rating-for-excellence-in-climate-change-mitigation-and-water-stewardship\/","url_meta":{"origin":89877,"position":5},"title":"Lupin Achieves Prestigious CDP Double ‘A’ Rating for Excellence in Climate Change Mitigation and Water Stewardship","author":"Team Small News","date":"January 25, 2026","format":false,"excerpt":"Lupin, a global pharmaceutical company, has achieved a significant milestone in its sustainability journey by earning a double 'A' rating from CDP (formerly known as the Carbon Disclosure Project) for its leadership in climate action and water security. This prestigious rating recognizes Lupin's efforts to reduce its environmental impact and\u2026","rel":"","context":"In "Lupin"","block_context":{"text":"Lupin","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/lupin\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89877","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89877"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89877\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89877"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89877"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89877"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}